Graves' disease complicated by concurrent thyroid eye disease and pretibial myxedema successfully treated with teprotumumab [PDF]
Clinical Case Reports (discontinued), 2022 We report a 51‐year‐old woman with thyroid eye disease and biopsy‐proven pretibial myxedema that was subsequently treated with teprotumumab with improvement.
Eva Chou +2 more
exaly +3 more sources
Pretibial myxedema in Grave's disease: A case report and treatment review of the literature [PDF]
Clinical Case Reports (discontinued)Key Clinical Message Pretibial myxedema is a rare skin lesion in Grave's disease, which required topical glucocorticoid administration in long‐term treatment. The patient's lesion has shrunk and become flatter than before treatment. Abstract We present a
van Bang Nguyen +2 more
exaly +3 more sources
A case of pretibial myxedema treated with teprotumumab [PDF]
JAAD Case Reports, 2021 Lauren Petit, MD +3 more
exaly +4 more sources
Pretibial myxedema in a patient with HIV and hypothyroid to hyperthyroid transformation [PDF]
JAAD Case Reports, 2023 Marcia Driscoll
exaly +4 more sources
Pretibial myxedema in a euthyroid patient: a case report [PDF]
Thyroid Research, 2021 Background Pretibial myxedema also known as localized myxedema, thyroid dermopathy, or infiltrative dermopathy and rarely as localized mucinosis is an infrequent manifestation of Graves’ disease.
Rediet Ambachew +6 more
doaj +2 more sources
Successful therapeutic approach in a patient with elephantiasic pretibial myxedema, [PDF]
Anais Brasileiros de Dermatologia, 2020 Localized pretibial myxedema is a dermopathy whose treatment is a challenge in dermatology, occurring in 0.5-4% of patients with Graves’ disease. This autoimmune thyroid condition stimulates the production of hyaluronic acid and glycosaminoglycans that ...
Marina Ferreira +3 more
doaj +2 more sources
Teprotumumab for Treatment of Pretibial Myxedema. [PDF]
JCEM Case Rep, 2023 Abstract Pretibial myxedema (PTM), also called thyroid dermopathy, is a dreaded and potentially debilitating manifestation of thyroid disease, more commonly Graves' disease, which can occur at any time over the course of the disease. No substantial long-term therapies have been able to target the condition, and management has typically ...
Reyes MP +3 more
europepmc +3 more sources
Integrated multi-platform metabolomics reveals fatty acid-mediated inflammatory signatures in pretibial myxedema [PDF]
Frontiers in EndocrinologyContextPretibial myxedema (PTM) is a refractory autoimmune dermopathy associated with Graves’ disease. Although metabolic dysregulation has been recognized in thyroid-associated disorders, the metabolic profile and its functional role in PTM remain ...
Jiayi Cai +9 more
doaj +2 more sources
Graves’ disease, myxedema and papillary thyroid carcinoma [PDF]
Medicina, 2022 Graves’ disease (GD) is the leading cause of hyperthyroidism and diffuse toxic goiter in iodine-sufficient geographical areas. GD is associated with classical manifestations such as ophthalmopathy and thyroid dermopathy, in addition to diffuse goiter ...
Luiz Augusto Marin Jaca +4 more
doaj +3 more sources
Pretibial Myxedema Associated with Euthyroid Hashimoto’s Thyroiditis: A Case Report [PDF]
Journal of Clinical and Diagnostic Research, 2014 Pretibial myxedema (PM) is an infiltrative dermopathy which is seen in grave’s disease. It is also associated with hypothyroidism, but is infrequently seen in Hashimoto’s thyroiditis. Lesions are seen commonly over pretibial region as non-pitting oedema
Pragya A Nair +2 more
doaj +2 more sources